Skip to content
yes i take peptides.
Library/For Wet/PT-141
FDA-approved (Vyleesi)For Wet+2 more★ Popular

PT-141

Bremelanotide. We read all 60 studies. The protocol is below.

Updated 19 May 2026Read 13 minEvidence ●●●●○Citations 60
+ Add to Stack
⚖ Compare side-by-side⎙ Print companion card

Free — puts PT-141 on your decision board.

The PT-141 Report · $19

Everything you need to start: dose, sourcing, safety, our verdict.

One purchase · yours forever

Built from 60 cited studies.

Status
FDA
Class
For Wet
Evidence
4/ 5●●●●○
FDA-approved
$19 ↓
Approved indication
$19 ↓
Mechanism target
$19 ↓
Read this if
  • you have HSDD and your MD mentioned Vyleesi
  • ED meds work for you mechanically but desire isn't there
  • you've heard about the "date-night peptide" on a podcast and want the medical read
  • **you want to know which lane to buy on** — Vyleesi (FDA, women on-label, ~$290/dose) vs compounded (off-label, ~$80–$300/mo, the dominant US channel) vs RUO (gray, ~$30–$70/mo, MT-II substitution risk)
Skip this if
  • **you want this to fix erections** — PT-141 acts on **desire (brain)**, not erection (vasculature). The 'I want to but can't' problem is a PDE5 inhibitor question
  • you have uncontrolled hypertension or cardiovascular disease — blood pressure goes up acutely (+6 mmHg systolic × 12 hr per Vyleesi PI §5.1)
  • you have a personal or family history of melanoma — same melanocortin family flag as MT-II
  • you can't tolerate nausea — it's the most common reason people quit (~40% in trials)
  • you're combining it with a full-dose PDE5 inhibitor — Vyleesi PI explicitly cautions against this
The 4 ways you can buy PT-141
Brand
✓
FDA-approved Rx
$900–$1,000 per 4-pack cash (~$290/dose)
The trial drug; on-label is for women only.
Compounded 503A
✓
Rx
$80–$300/mo (nasal spray or injectable)
Pharmacy-grade; the dominant off-label channel.
RUO (research-only)
✓
Sold 'for research only'
$30–$70/mo
Sometimes substituted with MT-II (stronger pigmentation and nausea — neither is what the buyer pai…
Gray market
✓
Unregulated overseas import
$5–$10/mo
Same upstream molecule as RUO. Crypto/Wise pay; per-mg cost is roughly 1/7 of RUO retail.
Click any lane for the full Sourcing breakdown.
First 90 days · PT-141
Weeks 1–2
On-demand class — works in 30–60 min on the day of use or it doesn't. The PT-141 effect either shows up at the proper dose or it's the wrong molecule for you.
Weeks 4–8
Side-effect accumulation is the real watch-for: facial hyperpigmentation (MC1 receptor), nausea with repeated use, mood changes.
Week 12 — decide
Decide based on the on-demand response pattern, not a slow build-up. There is no slow build-up here.
Quit if
  • Facial or scalp hyperpigmentation that doesn't fade after stopping for 2–4 weeks.
  • Persistent nausea on repeated use.
  • Zero response to 2–3 attempts at proper dose (one of these — it's not for everyone).
Identity

What it is.

PT-141 is bremelanotide, a melanocortin-receptor agonist developed out of the same research line as the tanning melanotan II. Somewhere in early trials, researchers noticed the men in the studies were getting erections. The program pivoted.

It was approved by the FDA in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women. That makes it one of the very few peptides on this site that is a real, approved, prescription drug for the indication people actually use it for.

The mechanism is unusual. Most sexual-function drugs (sildenafil, tadalafil) work on blood vessels — they're plumbing. PT-141 works on the brain, specifically the melanocortin-4 receptor in the hypothalamus. It changes the desire signal, not the blood flow.

Used off-label by both genders. Sold as online and as Vyleesi by prescription.

TL;DR

TL;DR. 30-second version.

The compressed verdict — what PT-141 actually is, what the human evidence shows, and the watch-for in three bullets. Locked.

Get the report · $19 ↓
Mechanism

Mechanism.

Mechanism · in the PT-141 report

How the molecule actually works — receptor profile, downstream signaling, what to expect mechanistically.

Get the report · $19 ↓
Evidence

Evidence. What we actually know in humans.

Evidence · in the PT-141 report

The trial breakdown — phase, n, primary endpoint, who funded, what hit, what didn't.

Get the report · $19 ↓
Human-Evidence Factbox
FDA-approved
$19 ↓
Approved indication
$19 ↓
Mechanism target
$19 ↓
Vyleesi dose
$19 ↓
Phase 3 RCTs
$19 ↓
Common side effect
$19 ↓
BP elevation peak (Vyleesi PI §5.1)
$19 ↓
PDE5 inhibitor co-administration
$19 ↓
RUO substitution risk
$19 ↓
Dose

Dose. The actual protocol.

Dose · in the PT-141 report

The specific protocol — dose, titration schedule, cycle pattern, frequency, route.

We read 60 studies to write this report.
Get the report · $19 ↓
Sourcing

Sourcing. Where the cohort actually buys.

Sourcing · in the PT-141 report

Sourcing breakdown — vendor methodology, red flags, our published test results, COA checklist.

We read 60 studies to write this report.
Get the report · $19 ↓
Safety

Safety. Side effects.

Safety · in the PT-141 report

The watch-for list — contraindications, drug interactions, monitoring labs, when to stop.

Get the report · $19 ↓
Editorial Position

Editorial position.

Editorial Position · in the PT-141 report

Our editorial position — explicit yes / no / depends, with the reasoning behind it.

Get the report · $19 ↓
Citations

Citations.

  1. 01Hedlund P. PT-141 Palatin. Current opinion in investigational drugs (London, England : 2000). 2004;5(4):456-62. PMID: 15134289.
  2. 02Nappi RE, et al. Medical Treatment of Female Sexual Dysfunction. The Urologic clinics of North America. 2022;49(2):299-307. PMID: 35428435.
  3. 03— Bremelanotide. 2021. PMID: 34436837.
  4. 04— Bremelanotide. 2025. PMID: 31369224.
  5. 05Dhillon S, et al. Bremelanotide: First Approval. Drugs. 2019;79(14):1599-1606. PMID: 31429064.
+Show all 60 citations
  1. 06Pettigrew JA, et al. Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment. Journal of midwifery & women's health. 2021;66(6):740-748. PMID: 34510696.
  2. 07Diamond LE, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. The journal of sexual medicine. 2006;3(4):628-638. PMID: 16839319.
  3. 08Sweeney P, et al. Targeting the central melanocortin system for the treatment of metabolic disorders. Nature reviews. Endocrinology. 2023;19(9):507-519. PMID: 37365323.
  4. 09Edinoff AN, et al. Bremelanotide for Treatment of Female Hypoactive Sexual Desire. Neurology international. 2022;14(1):75-88. PMID: 35076581.
  5. 10Mayer D, et al. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. The Annals of pharmacotherapy. 2020;54(7):684-690. PMID: 31893927.
  6. 11Spielmans GI, et al. Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder. Journal of sex research. 2024;61(4):540-561. PMID: 36809187.
  7. 12Clayton AH, et al. Safety Profile of Bremelanotide Across the Clinical Development Program. Journal of women's health (2002). 2022;31(2):171-182. PMID: 35147466.
  8. 13Spielmans GI. Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women. Journal of sex research. 2021;58(9):1085-1105. PMID: 33678061.
  9. 14Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics and gynecology. 2019;134(5):899-908. PMID: 31599840.
  10. 15Cipriani S, et al. An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder. Expert opinion on pharmacotherapy. 2023;24(1):15-21. PMID: 36242769.
  11. 16Pfaus JG, et al. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS spectrums. 2022;27(3):281-289. PMID: 33455598.
  12. 17Mintzes B, et al. Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent. Drug and therapeutics bulletin. 2021;59(12):185-188. PMID: 34642243.
  13. 18Simon JA, et al. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. Journal of women's health (2002). 2022;31(3):391-400. PMID: 35230162.
  14. 19Lee JH, et al. Pharmacotherapy for Sexual Dysfunction in Women. Current psychiatry reports. 2022;24(2):99-109. PMID: 35102537.
  15. 20How A, et al. Novel Pharmacologic Treatments of Female Sexual Dysfunction. Clinical obstetrics and gynecology. 2025;68(1):10-14. PMID: 39846877.
  16. 21Burton CS, et al. Pharmacologic therapeutic options for sexual dysfunction. Current opinion in obstetrics & gynecology. 2022;34(6):402-408. PMID: 36036468.
  17. 22Molinoff PB, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences. 2003;994:96-102. PMID: 12851303.
  18. 23— Bremelanotide (Vyleesi) for hypoactive sexual desire disorder. The Medical letter on drugs and therapeutics. 2019;61(1577):114-116. PMID: 31381550.
  19. 24Althof S, et al. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide. The journal of sexual medicine. 2019;16(8):1226-1235. PMID: 31277966.
  20. 25Shadiack AM, et al. Melanocortins in the treatment of male and female sexual dysfunction. Current topics in medicinal chemistry. 2007;7(11):1137-44. PMID: 17584134.
  21. 26— Bremelanotide: the female Viagra?. Expert review of endocrinology & metabolism. 2006;1(4):465-466. PMID: 30290453.
  22. 27Petherick A. Sexual arousal: Sex matters. Nature. 2017;550(7674):S2-S3. PMID: 28976951.
  23. 28Hussar DA. New Drugs 2020, part 2. Nursing. 2020;50(5):31-40. PMID: 32332502.
  24. 29Suzuki S, et al. Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression. Anticancer research. 2024;44(9):3875-3883. PMID: 39197897.
  25. 30Spana C, et al. Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials. Diabetes, obesity & metabolism. 2022;24(6):1084-1093. PMID: 35170192.
  26. 31Bardhan M, et al. Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases. Diseases (Basel, Switzerland). 2025;13(9). PMID: 41002740.
  27. 32Zhong Q, et al. Management of Hypertension with Female Sexual Dysfunction. Medicina (Kaunas, Lithuania). 2022;58(5). PMID: 35630054.
  28. 33Toledo RG, et al. Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options. Journal of minimally invasive gynecology. 2026;33(1):16-33.e3. PMID: 40543759.
  29. 34Barakeh D, et al. Pharmacotherapy of Hypoactive Sexual Desire Disorder in Premenopausal Women. The Annals of pharmacotherapy. 2025;59(2):148-161. PMID: 38767282.
  30. 35Kim NN. Finding Our Way From the Bench to the Bedside: The Ethos, Logos, and Pathos of Biomedical Research. Sexual medicine reviews. 2022;10(3):353-359. PMID: 35772848.
  31. 36Bridges TM. Pharmaceutical aphrodisia. Current topics in medicinal chemistry. 2007;7(11):1152. PMID: 17722370.
  32. 37Ila V, et al. Intravenous peptides and amino acids for erectile dysfunction: a narrative review of current applications and future directions. Expert opinion on pharmacotherapy. 2025;26(5):631-637. PMID: 40069591.
  33. 38Al Shaer D, et al. 2019 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals (Basel, Switzerland). 2020;13(3). PMID: 32151051.
  34. 39Safarinejad MR, et al. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. The Journal of urology. 2008;179(3):1066-71. PMID: 18206919.
  35. 40Pfaus J, et al. Bremelanotide: an overview of preclinical CNS effects on female sexual function. The journal of sexual medicine. 2007;4 Suppl 4:269-79. PMID: 17958619.
  36. 41Yuan XC, et al. Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin. Biomolecules. 2022;12(10). PMID: 36291616.
  37. 42Fuhrman J, et al. Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies. Expert review of clinical pharmacology. 2025;18(10):1-13. PMID: 41088800.
  38. 43Krupke H, et al. A biodegradable suction patch for sustainable transbuccal peptide delivery. Journal of controlled release : official journal of the Controlled Release Society. 2025;384:113947. PMID: 40513668.
  39. 44Carson SA. Boosting Female Sexual Response by RECONNECTing the Dots. Obstetrics and gynecology. 2019;134(5):897-898. PMID: 31599837.
  40. 45Koochaki P, et al. The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results. Journal of women's health (2002). 2021;30(4):587-595. PMID: 33538638.
  41. 46Simon JA, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstetrics and gynecology. 2019;134(5):909-917. PMID: 31599847.
  42. 47Hadley ME, et al. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-30. PMID: 16412534.
  43. 48Diamond LE, et al. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology. 2005;65(4):755-9. PMID: 15833522.
  44. 49Giliberto S, et al. A Comprehensive Review of Novel FDA-Approved Psychiatric Medications (2018-2022). Cureus. 2024;16(3):e56561. PMID: 38646400.
  45. 50Gelman F, et al. Flibanserin for hypoactive sexual desire disorder: place in therapy. Therapeutic advances in chronic disease. 2017;8(1):16-25. PMID: 28203348.
  46. 51Both S. Recent Developments in Psychopharmaceutical Approaches to Treating Female Sexual Interest and Arousal Disorder. Current sexual health reports. 2017;9(4):192-199. PMID: 29225554.
  47. 52Rosen RC, et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. International journal of impotence research. 2004;16(2):135-42. PMID: 14999221.
  48. 53Borland JM, et al. Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder. Neuropharmacology. 2025;267:110299. PMID: 39793696.
  49. 54Clayton AH, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women's health (London, England). 2016;12(3):325-37. PMID: 27181790.
  50. 55Hellstrom WJ. Clinical applications of centrally acting agents in male sexual dysfunction. International journal of impotence research. 2008;20 Suppl 1:S17-23. PMID: 18552830.
  51. 56da Silva Lara LA, et al. Female sexual dysfunctions: an overview on the available therapeutic interventions. Minerva obstetrics and gynecology. 2022;74(3):249-260. PMID: 35147017.
  52. 57Sauter M, et al. Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics. Journal of pharmaceutical and biomedical analysis. 2020;186:113276. PMID: 32353679.
  53. 58Clayton AH, et al. Evaluation and Management of Hypoactive Sexual Desire Disorder. Sexual medicine. 2018;6(2):59-74. PMID: 29523488.
  54. 59Ronghe V, et al. Understanding Hypoactive Sexual Desire Disorder (HSDD) in Women: Etiology, Diagnosis, and Treatment. Cureus. 2023;15(11):e49690. PMID: 38161863.
  55. 60Shadiack AM, et al. Preclinical effects of melanocortins in male sexual dysfunction. International journal of impotence research. 2008;20 Suppl 1:S11-6. PMID: 18552829.
The PT-141 Report · $19

Everything you need to start.

Dose, sourcing, safety, our verdict. One purchase. Yours forever.

Built from 60 cited studies.

Or get every report. All reports — $99 once · Pro — $29/mo.
Compare tiers →